Goodwin Advises Incyte in Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding Incyte’s Hematology Portfolio into Bleeding Disorders

The Life Sciences team advised Incyte (Nasdaq: INCY) in its definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion upfront, with Star Therapeutics eligible to receive up to $750 million in additional payments upon the achievement of sales milestones, for total potential consideration of up to $2.0 billion subject to customary closing adjustments. The equity acquisition will add VGA039, a Phase 3 investigational monoclonal antibody targeting Protein S for the treatment of von Willebrand disease, to Incyte’s hematology portfolio. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2026.

Incyte is a global biopharmaceutical company focused on advancing innovative medicines through deep scientific expertise and a patient-centered approach. The company has built an established portfolio of first-in-class medicines and a broad pipeline of next-generation therapies across its core franchises of Hematology, Oncology, and Inflammation & Autoimmunity.

The Goodwin team was led by Stuart Cable, Lisa Haddad, Jennifer Porter, and Stephanie Isaia and included Noelle Dubiansky, Arman Oruc, Simone Waterbury, Sarah Bock, Morgan Frisoli, Christina Lewis, Carl Morales, Jacqueline Klosek, Julie Tibbets, Matthew Wetzel, Reid Bagwell, Daniel Karelitz, Carrie Miller, Jacob Osborn, Alice Choi, Jess Gorski, Alastair Papworth, Austin Church, Miho Kaneko, Jonathan Ng, Daniel Farraye, Kelvin Tsz Ho Chan, Chase Gorland, Gozde Guckaya, and Ben Rodrigues.

For more information, please read the press release.

Goodwin Advises Incyte in Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding Incyte’s Hematology Portfolio into Bleeding Disorders

Related Content

Expanding Corporate Criminal Liability in the UK: Key Impacts and Considerations for Organisations and Investors

Alvotech’s BLA for Vedolizumab Biosimilar First to be Accepted by FDA

Chime Biologics and Daewoong Pharmaceutical Partner on Dupilumab Biosimilar

BIOSECURE Update – 1260H List Released

Supreme Court Declines to Review $220 Million Drug Pricing Judgment Against Eli Lilly

Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars

Polpharma and Tuteur Enter License for the Commercialization of a Biosimilar Targeting Autoimmune Diseases in Latin America

Samsung Bioepis Launches OPUVIZ in Europe

Goodwin Represents Parabilis Medicines in Strategic Collaboration With Regeneron Pharmaceuticals for Up to $2.3 Billion

Goodwin Advises Engitix on Strategic Collaboration With GSK for £44.5 Million Upfront and Up to £118 Million in Milestones

Goodwin Guides Parabilis Medicines on Upsized $770.5 Million Initial Public Offering and $75 Million Private Placement to Regeneron Pharmaceuticals

Goodwin Guides City Therapeutics on $99.5 Million Series B Financing

The Legal 500 US 2026 Recognizes 47 Goodwin Practices and 185 Lawyers

Goodwin Advises SonoThera on Oversubscribed $125 Million Series B Financing

Innovafeed is Scaling Up and Entering a New Growth Phase Backed by a €51 Million Funding Round

Goodwin Advises Nurix Therapeutics on Global Collaboration With Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg for $700 Million Upfront and Up to $2.3 Billion in Total

Life Sciences

Life Sciences M&A

Mergers & Acquisitions